Andrew G. Polson

4.2k total citations
41 papers, 1.8k citations indexed

About

Andrew G. Polson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew G. Polson has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 21 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew G. Polson's work include Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (17 papers) and CAR-T cell therapy research (16 papers). Andrew G. Polson is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (17 papers) and CAR-T cell therapy research (16 papers). Andrew G. Polson collaborates with scholars based in United States, France and United Kingdom. Andrew G. Polson's co-authors include Michael W. Klymkowsky, Joseph A. Dent, Brenda Bass, Laurie A. Maynell, Shang‐Fan Yu, Bing Zheng, Thomas H. Pillow, Steven C. Pomerantz, Pamela F. Crain and Don Ganem and has published in prestigious journals such as Blood, Molecular and Cellular Biology and Development.

In The Last Decade

Andrew G. Polson

40 papers receiving 1.8k citations

Peers

Countries citing papers authored by Andrew G. Polson

Since Specialization

Citations

This map shows the geographic impact of Andrew G. Polson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew G. Polson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew G. Polson more than expected).

Fields of papers citing papers by Andrew G. Polson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew G. Polson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew G. Polson. The network helps show where Andrew G. Polson may publish in the future.

Co-authorship network of co-authors of Andrew G. Polson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew G. Polson. A scholar is included among the top collaborators of Andrew G. Polson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew G. Polson. Andrew G. Polson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing 2023 ·Cancer Immunology Research ·Rickvinder Besla, Elicia Penuel, (unknown), Ely Cosino, (unknown), Mike Dillon, Greg A. Lazar, Dorothee Nickles, Christoph Spiess, Shang‐Fan Yu, Andrew G. Polson	6
2	Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas 2023 ·Blood ·Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit Assouline, Nancy L. Bartlett, Lihua E. Budde, Matthew J. Matasar, Hartmut Koeppen, Emily Piccione, (unknown), Michael C. Wei, Shen Yin, Elicia Penuel	34
3	Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma 2023 ·Blood ·Victor Maximov, Christopher R. Bolen, Andrew G. Polson, Elicia Penuel, Elisabeth A. Lasater	1
4	Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study 2022 ·Clinical Cancer Research ·Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, (unknown), Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach	21
5	An Anti–CD22- seco -CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models 2020 ·Molecular Cancer Therapeutics ·Shang‐Fan Yu, Donna W. Lee, Bing Zheng, Geoffrey Del Rosario, Douglas D. Leipold, Helen Booler, Fiona Zhong, Montserrat Carrasco‐Triguero, Kyu Hong, Peter Yan, Rebecca K. Rowntree, Melissa M. Schutten, Thomas H. Pillow, Jack Sadowsky, Peter S. Dragovich, Andrew G. Polson	8
6	Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues 2019 ·Drug Metabolism and Disposition ·Donglu Zhang, Peter S. Dragovich, Shang‐Fan Yu, Yong Ma, Thomas H. Pillow, Jack Sadowsky, Dian Su, Wei Wang, Andrew G. Polson, S. Cyrus Khojasteh, Cornelis E. C. A. Hop	24
7	An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia 2018 ·Clinical Cancer Research ·Bing Zheng, Shang‐Fan Yu, Geoffrey Del Rosario, Steven R. Leong, Genee Y. Lee, Rajesh Vij, Cecilia Chiu, Wei‐Ching Liang, Yan Wu, Cécile Chalouni, Jack Sadowsky, Vanessa Clark, (unknown), Kirsten Achilles Poon, (unknown), Thomas H. Pillow, Melissa M. Schutten, John A. Flygare, Andrew G. Polson	49
8	Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates 2018 ·Molecular Cancer Therapeutics ·Donglu Zhang, Shang‐Fan Yu, S. Cyrus Khojasteh, Yong Ma, Thomas H. Pillow, Jack Sadowsky, Dian Su, Katherine R. Kozak, Keyang Xu, Andrew G. Polson, Peter S. Dragovich, Cornelis E. C. A. Hop	31
9	Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates 2017 ·Cancer Research ·(unknown), Josefa Chuh, Yong Ma, Donglu Zhang, Katherine R. Kozak, Yichin Liu, Thomas H. Pillow, Jack Sadowsky, Tommy K. Cheung, Qui Phung, Benjamin Haley, (unknown), Robert W. Akita, Mark X. Sliwkowski, Andrew G. Polson	98
10	Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers 2017 ·Journal of Medicinal Chemistry ·Stephen J. Gregson, Luke A. Masterson, BinQing Wei, Thomas H. Pillow, Susan D. Spencer, (unknown), Shang‐Fan Yu, Helga Raab, Jeffrey Lau, Guangmin Li, Gail D. Lewis Phillips, Janet Gunzner-Toste, Brian S. Safina, Rachana Ohri, Martine Darwish, Katherine R. Kozak, Josefa dela Cruz-Chuh, Andrew G. Polson, John A. Flygare, Philip W. Howard	27
11	Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs 2017 ·Bioorganic & Medicinal Chemistry Letters ·Peter S. Dragovich, Fabio Broccatelli, Jinhua Chen, Peter W. Fan, Hoa Thi Le, Weiguang Mao, Thomas H. Pillow, Andrew G. Polson, John Wai, Zijin Xu, Hui Yao, Donglu Zhang	9
12	Preclinical Characterization of Combinability and Potential Synergy of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody with Chemotherapy and PD-1/PD-L1 Blockade 2016 ·Blood ·Liping Sun, Peiyin Wang, Robyn Clark, Maria Hristopoulos, Diego Ellerman, Mary Mathieu, Yu‐Waye Chu, Hong Wang, Klára Tótpál, Allen Ebens, Andrew G. Polson, Stephen E. Gould	2
13	A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs 2015 ·Clinical Cancer Research ·Shang‐Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan D. Spencer, Helga Raab, Robert Soriano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John A. Flygare, Andrew G. Polson	125
14	The cryptophycins as potent payloads for antibody drug conjugates 2015 ·Bioorganic & Medicinal Chemistry Letters ·Vishal Verma, Thomas H. Pillow, (unknown), Guangmin Li, Gail D. Lewis Phillips, Andrew G. Polson, Helga Raab, Susan D. Spencer, Bing Zheng	51
15	Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs. 2013 ·Cancer Research ·Andrew G. Polson, Bing Zheng, MaryAnn Go, (unknown), Shang‐Fan Yu, Susan D. Spencer, Robert Cohen, Michele Caruso, John A. Flygare, Paul Polakis	1
16	FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma 2012 ·Molecular Cancer Therapeutics ·Kristi Elkins, Bing Zheng, MaryAnn Go, Dionysos Slaga, Changchun Du, Suzie J. Scales, Shang‐Fan Yu, Jacqueline McBride, Ruth de Tute, Andy C. Rawstron, Andrew Jack, Allen Ebens, Andrew G. Polson	69
17	Hepatitis Delta Virus RNA Editing Is Highly Specific for the Amber/W Site and Is Suppressed by Hepatitis Delta Antigen 1998 ·Molecular and Cellular Biology ·Andrew G. Polson, Herbert L. Ley, Brenda Bass, John Casey	74
18	The mechanism of adenosine to inosine conversion by the double-stranded RNA unwinding/modifying activity: a high-performance liquid chromatography-mass spectrometry analysis 1991 ·Biochemistry ·Andrew G. Polson, Pamela F. Crain, Steven C. Pomerantz, James A. McCloskey, Brenda Bass	112
19	Polar asymmetry in the organization of the cortical cytokeratin system of Xenopus laevis oocytes and embryos 1987 ·Development ·Michael W. Klymkowsky, Laurie A. Maynell, Andrew G. Polson	107
20	Two antigen-antibody systems in serum hepatitis: preparation of immunoglobulins and their reaction with Australia antigen and particles in liver cell homogenates. 1973 ·PubMed ·(unknown), Andrew G. Polson, A. Kipps, (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact